GEC255

GEC255 is an orally bioavailable small molecule inhibitor that selectively targets the oncogenic Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C mutation, a driver of tumorigenesis in several cancers. By binding to and inhibiting the mutant KRAS G12C protein, GEC255 blocks downstream signaling pathways involved in cell proliferation and survival. It has demonstrated promising antitumor activity in advanced non-small cell lung cancer (NSCLC) patients harboring the KRAS G12C mutation, including those who have failed prior therapies. In Phase 1 clinical trials, it showed high selectivity for its target with favorable safety and pharmacokinetic profiles; most adverse events were mild or moderate (grade 1 or 2), such as diarrhea, elevated ALT, rash, and anemia. The drug is being developed by GenEros Biopharma[1][3][4][6][7].

Other names

KRAS G12C inhibitor GEC-255